Recently Developed Therapeutic Agents for B-cell Non-Hodgkin Lymphoma.
10.3904/kjm.2015.88.3.247
- Author:
Byeong Bae PARK
1
Author Information
1. Division of Hematology-Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. bbpark@hanyang.ac.kr
- Publication Type:Review
- Keywords:
Treatment;
B-cell lymphoma;
Lymphoma
- MeSH:
Antibodies, Monoclonal;
B-Lymphocytes*;
Drug Therapy;
Hope;
Humans;
Lymphoma;
Lymphoma, B-Cell;
Lymphoma, Non-Hodgkin*;
Membrane Proteins;
Treatment Failure;
Tumor Microenvironment
- From:Korean Journal of Medicine
2015;88(3):247-251
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
While most B-cell lymphomas are cured by chemotherapy, in recent years research interest has focused on the development of monoclonal antibodies and small molecules targeting membrane proteins, components of signaling pathways or tumor microenvironment, which are factors essential for the development and progression of lymphomas. Some of these new drugs have shown substantial clinical activity in phase I and small phase II studies in patients with relapsed and refractory disease, with response rates of up to 50-60% in some cases. These results give hope for patients who have standard treatment failure; however, their incorporation into commonly used regimens also represents a significant challenge for the future.
